Human leucocyte antigen class I and class II antigen expression in malignant fibrous histiocytoma, fibrosarcoma and dermatofibrosarcoma protuberans is significantly downregulated

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 11, 2010, Pages 1326-1332

  Meissner, M ^a   Konig V ^a   Hrgovic, I ^a,b   Valesky, E ^a   Kaufmann, R ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antigen processing; Human leucocyte antigen class I and II; Immune escape

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CHILD; CONTROLLED STUDY; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SCHOOL CHILD;

EID: 78649744167     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03644.x     Document Type: Article

References (49)

1. Hung K, Hayashi R, Lafond-Walker A et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 88: 2357-2368.
2. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-594.
3. Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA. HLA class II molecules in tumour immunology: Prognostic marker and target for immune modulation. Immunobiology 2006; 211: 619-625.
4. Gerloni M, Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol 2005; 27: 37-48.
5. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997; 18: 89-95.
6. Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
7. Seliger B, Maeurer MJ, Ferrone S. Antigen processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-464.
8. Restifo N, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
9. Seliger B. Different regulation of HLA class I antigen processing components in human tumors. J Immunotoxicol 2008; 5: 361-367.
10. Cromme FV, van Bommel PFL, Walboomers JMM et al. Differences in HLA and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumors. Br J Cancer 1994; 69: 1176-1181.
11. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and TAP downregulation in high grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737-742.
12. Kageshita T, Hirai S, Ono T et al. Downregulation of HLA class I antigen- processing molecules in malignant melanoma: Association with disease progression. Am J Pathol 1999; 154: 745-754.
13. Redondo M, Concha A, Ruiz-Cabello F et al. Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas. Cancer Detect Prev 1997; 21: 22-28. (Pubitemid 27307067)
14. Shi B, Vinyals A, Alia P et al. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription. Implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 2006; 38: 544-562.
15. Mortara L, Castellani P, Meazza R et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 2006; 12: 3435-3443.
16. Thompson JA, Dissanayake SK, Ksander BR et al. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumorspecific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 2006; 66: 1147-1154.
17. Baskar S, Azarenko V, Garcia Marshall E et al. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 1994; 155: 123-133.
18. Humphreys RE, Hillman GG, von Hofe E et al. Forcing tumor cells to present their own tumor antigens to the immune system: A necessary design for an efficient tumor immunotherapy. Cell Mol Immunol 2004; 1: 180-185.
19. Ostrand-Rosenberg S. CD4+ T lymphocytes: A critical component of antitumor immunity. Cancer Invest 2005; 23: 413-419.
20. Andersen SN, Rognum TO, Lund E et al. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993; 68: 80-85.
21. Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994; 56: 314-319.
22. Esteban F, Concha A, Huelin C et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1998; 43: 436-442.
23. Jackson PA, Green MA, Marks CG et al. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 1996; 38: 85-89.
24. Matsushita K, Takenouchi T, Kobayashi S et al. HLA-DR antigen expression in colorectal carcinomas: Influence of expression by IFNgamma in situ and its association with tumour progression. Br J Cancer 1996; 73: 644-648.
25. Sikorska B, Danilewicz M, Wagrowska-Danilewicz M. HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric study. Apmis 1999; 107: 383-388.
26. Bosshart H, Jarrett RF. Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells. Blood 1998; 92: 2252-2259.
27. Levi F, La Vecchia C, Randimbison L et al. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer 1999; 35: 1711-1716.
28. Rouhani P, Fletcher CD, Devesa SS et al. Cutaneous soft tissue sarcoma incidence patterns in the U. S. : An analysis of 12,114 cases. Cancer 2008; 113: 616-627.
29. Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol 2004; 43: 530-535.
30. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer 2004; 1: 101.
31. Roholl PJ, Kleyne J, Van Unnik JA. Characterization of tumor cells in malignant fibrous histiocytomas and other soft-tissue tumors, in comparison with malignant histiocytes. II. Immunoperoxidase study on cryostat sections. Am J Pathol 1985; 121: 269-274. (Pubitemid 16230694)
32. Lawson CW, Fisher C, Gatter KC. An immunohistochemical study of differentiation in malignant fibrous histiocytoma. Histopathology 1987; 11: 375-383.
33. Regezi JA, Zarbo RJ, Tomich CE et al. Immunoprofile of benign and malignant fibrohistiocytic tumors. J Oral Pathol 1987; 16: 260-265.
34. Xiong Y, Guo H, Zhang S et al. Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans. Beijing Da Xue Xue Bao 2008; 40: 395-400.
35. Mechtersheimer G, Staudter M, Majdic O et al. Expression of HLAA, B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int J Cancer 1990; 46: 813-823.
36. Imai Y, Yamakawa M, Sato T et al. Malignant fibrous histiocytoma: Similarities to the "fibrohistiocytoid cells" in chronic inflammation. Virchows Arch A Pathol Anat Histopathol 1989; 414: 285-298.
37. Cerruti F, Martano M, Petterino C et al. Enhanced expression of interferon- gamma-induced antigen-processing machinery components in a spontaneously occurring cancer. Neoplasia 2007; 9: 960-969.
38. Aptsiauri N, Carretero R, Garcia-Lora A et al. Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008; 57: 1727-1733.
39. Seliger B, Stoehr R, Handke D et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2010; 59: 529-540.
40. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57: 1719-1726.
41. Meissner M, Reichert TE, Kunkel M et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin Cancer Res 2005; 11: 2552-2560.
42. Cabrera CM, Jiménez P, Cabrera T et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Beta2- microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003; 61: 211-219.
43. Stam NJ, Vroom TM, Peters PJ et al. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryoimmuno- electron microscopy. Int Immunol 1990; 2: 113-125.
44. Armstrong TD, Clements VK, Martin BK et al. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997; 94: 6886-6891.
45. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990; 144: 4068-4071.
46. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-1493.
47. Cabrera T, Lopez-Nevot MA, Gaforio JJ et al. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52: 1-9.
48. Rodriguez T, Mendez R, Del Campo A et al. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 2007; 59: 123-133.
49. Meissner M, Whiteside TL, van Kuik-Romein P et al. Loss of interferon- gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: Evidence for post-transcriptional as well as epigenetic regulation. Br J Dermatol 2008; 158: 930-940.